# Safety, Tolerability, and Pharmacokinetics of RCS-21 in Healthy Volunteers.

> **NCT06752122** · PHASE1 · RECRUITING · sponsor: **RNATICS GmbH** · enrollment: 24 (estimated)

## Conditions studied

- Healthy Volunteers
- Safety
- Tolerability
- Pharmacokinetics

## Interventions

- **DRUG:** Placebo (SAD)
- **DRUG:** RCS-21 (SAD)

## Key facts

- **NCT ID:** NCT06752122
- **Lead sponsor:** RNATICS GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-18
- **Primary completion:** 2026-06
- **Final completion:** 2026-08
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2025-11-20

## Collaborators

- LungenClinic Grosshansdorf

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06752122

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06752122, "Safety, Tolerability, and Pharmacokinetics of RCS-21 in Healthy Volunteers.". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT06752122. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*